Since its incorporation in February 2021, Tidetron Bioworks has been recognized by many famous PE/VCs.
Recently, Tidetron Bioworks said that it had completed Series A+ of financing of more than USD 100 million, led by IDG Capital and followed by Legend Capital. The company disclosed that this financing round would be mainly used for the research and production of new pipelines, including the research and large-scale mass production of commodities, new materials, pharmaceutical intermediates and other products.
Since its incorporation in February 2021, Tidetron Bioworks has been recognized by many famous PE/VCs. In addition to the trend of synthetic biology, the key is the fact that the company has solved the mass production of various synthetic substances: dozens of substances such as small peptides and erythritol have achieved mass production. The company sells about 30 kinds of substances. At present, it focuses on the added fields such as consumer goods.
Zhiqian Zhang, the company's founder, said that its medium- and short-term development goal is to expand the existing synthetic materials and their application fields. Next, state innovation will develop new materials for bulk commodities and benefit people's daily life to a greater extent.